Skip to main content
. Author manuscript; available in PMC: 2021 Oct 18.
Published in final edited form as: Lancet. 2020 Feb 1;395(10221):371–383. doi: 10.1016/S0140-6736(19)33005-3

Table 2:

Risk for type 2 therapeutics

Observed risks Hypothetical risks
Mepolizumab Herpes zoster Parasitic infections, malignancy, obesity or metabolic dysfunction
Reslizumab Anaphylaxis Parasitic infections, malignancy, obesity or metabolic dysfunction
Benralizumab Prolonged decrease in eosinophil counts Parasitic infections, malignancy, obesity or metabolic dysfunction
Dupilumab Eosinophilia, conjunctivitis Parasitic infections, obesity or metabolic dysfunction, eosinophilic granulomatosis with polyangiitis

All medications report low and similar frequencies for injection site reactions (2–10%) and hypersensitivity reactions (<1–3%).